Bedrijfsoverzicht
Protalix BioTherapeutics, Inc. is a biopharmaceutical entity dedicated to the development, production, and commercialization of recombinant therapeutic proteins utilizing its proprietary ProCellEx plant cell-based protein expression system. The company operates within the Healthcare sector, specifically inside the Biotechnology industry, where it focuses on delivering specialized treatments such as Elelyso for the management of Gaucher disease. Currently, the organization employs 226 individuals and holds a market capitalization of $185.31 million, with trailing twelve-month revenue reported at $52.74 million. These financial metrics indicate that Protalix BioTherapeutics functions as a mid-cap entity within the biotech landscape, possessing a significant cash reserve relative to its current market valuation, yet generating negative net income which is typical for companies in the development and early commercialization phases of their product lifecycle.
Financiële gezondheid
The company reported a revenue of $52.74 million over the trailing twelve months, while the net income stands at -$6,604,000 and EBITDA is recorded at -$4,035,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development activities, manufacturing overheads, or commercialization costs that exceed gross profit margins. Free cash flow for the period is -$12,196,875, indicating that the company is burning cash at a rapid pace, which limits its immediate financial flexibility and necessitates ongoing access to capital markets or existing cash reserves to sustain operations. The gross margin is calculated at 13.0%, suggesting that the cost of goods sold is relatively high compared to revenue, while the operating margin of -51.1% and profit margin of -12.5% highlight severe inefficiencies in covering operating expenses and the inability to generate profit from sales at the current scale. On the liability side, the company holds $30.27 million in cash against $8.32 million in debt, resulting in a debt-to-equity ratio of 17.25, which presents a complex picture where low absolute debt levels coexist with a high leverage ratio due to a likely small equity base. Despite the negative earnings, the current ratio of 2.51 indicates a strong short-term liquidity position, as current assets are more than double the current liabilities, providing a buffer against immediate financial obligations. Furthermore, the return on equity is -14.4% and the return on assets is -4.4%, metrics that collectively reveal that management is currently unable to generate positive returns on the shareholders' investment or the total asset base, reflecting the capital-intensive nature of the biotechnology sector.
Waarderingsbeoordeling
The valuation metrics present a distinct divergence between historical performance and future expectations, as the trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is 3.71. This significant difference implies that the market expects a substantial turnaround in earnings trajectory in the future, valuing the stock based on anticipated profitability rather than current realized performance. The price-to-book ratio stands at 3.83, indicating that the market is pricing the company at a premium of nearly four times its net asset value, a common phenomenon in biotech firms where intangible assets and intellectual property are not fully captured on the balance sheet. Alternative valuation measures further define the company's standing, with a price-to-sales ratio of 3.51 and an EV/EBITDA of -40.49, suggesting that investors are willing to pay a multiple of current sales despite the negative earnings power, driven by the potential value of the pipeline. In terms of trading range, the 52-week high is $3.19 and the 52-week low is $1.32, meaning the current price sits at the lower end of this volatility range, reflecting the uncertainty surrounding the company's near-term earnings generation. Additionally, the beta value of -0.09 is highly unusual for an equity security, suggesting that the stock's price movements are virtually uncorrelated with the broader market or move inversely to market indices, which significantly alters the risk profile for a diversified portfolio.
Growth & Income
The revenue growth year-over-year is -49.9%, while earnings growth is N/A, indicating a contraction in sales that directly correlates with the negative earnings trajectory. Since the company is not generating positive earnings, the concept of earnings growing faster than revenue is inapplicable, as the negative earnings growth is a direct consequence of the declining revenue base and high fixed costs. As a non-dividend payer, Protalix BioTherapeutics maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company reinvests all available resources back into research, development, and commercialization efforts rather than distributing cash to shareholders. The overall growth and income profile is defined by a contractionary revenue phase with no current income distribution, positioning the stock as a speculative play on future product successes rather than an income-generating or stable growth investment at this specific moment in time.